Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00442221
Recruitment Status : Completed
First Posted : March 1, 2007
Last Update Posted : March 1, 2007
Sponsor:
Information provided by:
POZEN

Brief Summary:
The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines

Condition or disease Intervention/treatment Phase
Migraine Headaches Drug: Sumatriptan and Naproxen sodium Phase 3

Expanded Access : POZEN has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Detailed Description:
The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines, with an optional second dose at least 2 hours following the first dose, if needed. Combo Formulation will be administered on average at least twice per month for 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 500 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Repeat Dose Study Of The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months
Study Start Date : May 2004
Study Completion Date : August 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache Migraine




Primary Outcome Measures :
  1. END POINTS
  2. Adverse events, physical examination findings, vital signs and clinical laboratory findings will be evaluated.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is a male or a female who is not pregnant or is not lactating. A female is eligible to enter and participate in this study if she is of:

    • Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,
    • Child-bearing potential, has a negative pregnancy test (urine or serum) at screen, and employs one of the following acceptable measures of contraception:

      • Complete abstinence from intercourse from 2 weeks prior to administration of the investigational product, throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the investigational drug (a minimum of 24 hrs); subjects utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for randomized treatment; or,
      • Female sterilization; or,
      • Sterilization of male partner; or,
      • Implants of levonorgestrel; or,
      • Injectable progestogen; or,
      • Oral contraceptive (combined or progestogen only); or,
      • Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year (not all IUDs meet this criterion); or,
      • Any other method with published data showing that the lowest expected failure rate for that method is less than 1% per year.
      • Barrier method only if used in combination with any of the above acceptable methods
  2. Subject is 18 – 65 years of age.
  3. Subject’s first migraine occurred prior to the age of 50 years.
  4. Subject has at least a 6-month history, immediately prior to screening, of migraine with or without aura according to the International Headache Society criteria (see Appendix I).
  5. Subject experienced an average migraine headache frequency of 2-6 moderate or severe attacks per month in the previous 6 months.
  6. Subject is able to distinguish his/her migraine attacks as discrete from any other types of headaches.
  7. Subject is willing and able to give written informed consent prior to entry into the study.

Exclusion Criteria:

  1. Subject has received another investigational drug within the 4 weeks preceding this study, or subject was enrolled in this study previously.
  2. Subject has any concurrent medical or psychiatric condition that may affect the interpretation of efficacy and/or safety data or which otherwise contraindicates participation in a clinical trial with a new chemical entity. This includes, but is not limited to, chronic unstable debilitating diseases such as HIV infection, multiple sclerosis, cancer, etc.
  3. Subject has a clinically significant disorder that, in the opinion of the investigator, would result in the subject’s inability to understand and comply with the requirements of the study.
  4. Subject has a history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes or other significant underlying cardiovascular diseases.
  5. Subject has a history of cardiac arrhythmias requiring medication or a history of a clinically significant electrocardiogram (ECG) abnormality that, in the investigator’s opinion, contraindicates participation in this study.
  6. Subject has a history of cerebrovascular abnormalities including stroke and/or transient ischemic attacks.
  7. Subject who, in the investigator’s opinion, is likely to have unrecognized cardiovascular disease, based on history or the presence of risk factors (e.g. hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of coronary artery disease, female with surgical or physiological menopause, or male over 40 years of age).
  8. Subject has evidence or history of ischemic abdominal syndromes, peripheral vascular disease or Raynaud syndrome.
  9. Subject has uncontrolled hypertension at screening (sitting systolic pressure >160 millimeters of mercury (mmHg), diastolic pressure >95 mmHg).
  10. Subject has a history of epilepsy or conditions associated with a lowered seizure threshold.
  11. Subject has a history of basilar or hemiplegic migraine.
  12. Subject has a history of impaired hepatic or renal function that, in the investigator’s opinion, contraindicates participation in this study; or the subject has any other abnormal laboratory value of clinical significance for this study.
  13. Subject has a history of non-migraine (i.e., tension-type, sinus, etc.) headache frequency greater than or equal to 15 days/month in each of the 3 months prior to screening.
  14. Subject has had >6 migraine attacks/month in either of the 2 months prior to screening.
  15. Subject is currently taking a monoamine oxidase inhibitor (MAOI), has taken a MAOI within the 2 weeks prior to screening, or plans to take a MAOI within 2 weeks after treatment.
  16. Subject is currently taking any anti-coagulant (e.g., warfarin) or NSAID (except doses of aspirin ≤325 mg per day being used for cardiovascular prophylaxis) on a regular basis.
  17. Subject is currently taking, or has taken in the previous 3 months, a migraine prophylactic medication containing ergotamine, an ergot derivative (dihydroergotamine), or methysergide.
  18. Subject is currently taking, or has taken in the previous 4 weeks, herbal preparations containing St. John’s Wort (Hypericum perforatum)
  19. Subject has hypersensitivity, intolerance, or contraindication to the use of sumatriptan or naproxen sodium, any of its components, or any other 5-HT1 receptor agonist.
  20. Subject has a history of allergic reactions to naproxen preparations, including subject in whom aspirin or other NSAID drugs induce the syndrome of asthma, rhinitis, and nasal polyps.
  21. Subject is pregnant, actively trying to become pregnant, or breast-feeding.
  22. Subject is of childbearing potential and not using adequate contraceptive measures.
  23. Subject has a recent history (in the past 3 months) suggestive of alcohol or drug abuse or dependence, including the overuse (abuse) of ergotamines and/or narcotics to treat migraines. Ergotamine abuse is daily use for 14 consecutive days or intermittent consumption exceeding 10 mg per week for any two weeks.
  24. Subject has participated in an investigational drug trial within the previous four weeks, or plans to participate in another study at any time during the period of this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00442221


Locations
Layout table for location information
United States, North Carolina
POZEN Inc.
Chapel Hill, North Carolina, United States, 27517
Headache Wellness Center
Greensboro, North Carolina, United States, 27401
Sponsors and Collaborators
POZEN
Investigators
Layout table for investigator information
Study Director: David Taylor POZEN

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00442221     History of Changes
Other Study ID Numbers: MT400-303
First Posted: March 1, 2007    Key Record Dates
Last Update Posted: March 1, 2007
Last Verified: February 2007

Keywords provided by POZEN:
Migrane headaches

Additional relevant MeSH terms:
Layout table for MeSH terms
Sumatriptan
Migraine Disorders
Headache
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Pain
Neurologic Manifestations
Signs and Symptoms
Naproxen
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents